Table 1.
Characteristic | Value | |
---|---|---|
Number of included patients | 46 | |
Age, mean (range), years | 54 (33–72) | |
Postmenopausal, n (%) | 20 | 43 |
Histological assessment, n (%) | ||
Invasive ductal carcinoma | 40 | 87 |
Invasive lobular carcinoma | 4 | 9 |
Metaplastic carcinoma | 2 | 4 |
TNM stage at diagnosis, n (%) | ||
T2N0 | 13 | 28 |
T2N+ | 17 | 37 |
T3N0 | 5 | 11 |
T3N+ | 9 | 20 |
T4N+ | 2 | 4 |
Molecular characteristics, n (%) | ||
Luminal A | 3 | 6 |
Luminal B | 16 | 35 |
Luminal B HER2+ | 6 | 13 |
HER2+ | 9 | 20 |
Triple negative | 12 | 26 |
Histopathological response to NAC in surgical specimen (RECIST 1.1), n (%) | ||
Complete response (pCR) | 8 | 17 |
Partial response (pPR) | 32 | 70 |
Stable disease (pSD) | 5 | 11 |
Progressive disease (pPD) | 1 | 2 |
Surgical treatment, n (%) | ||
Lumpectomy | 28 | 61 |
Mastectomy | 18 | 39 |
HER2 human epidermal growth factor receptor 2, NAC neoadjuvant chemotherapy, RECIST response evaluation criteria in solid tumors, pCR pathological complete response, pPR pathological partial response, pSD pathological stable disease, pPD pathological progressive disease